CY1120670T1 - Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) - Google Patents

Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)

Info

Publication number
CY1120670T1
CY1120670T1 CY181100729T CY181100729T CY1120670T1 CY 1120670 T1 CY1120670 T1 CY 1120670T1 CY 181100729 T CY181100729 T CY 181100729T CY 181100729 T CY181100729 T CY 181100729T CY 1120670 T1 CY1120670 T1 CY 1120670T1
Authority
CY
Cyprus
Prior art keywords
tfpi
antibodies
antibodies against
tissue factor
against tissue
Prior art date
Application number
CY181100729T
Other languages
English (en)
Inventor
Zhuozhi Wang
John E Murphy
Junliang Pan
Haiyan Jiang
Bing Liu
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41664165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120670(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CY1120670T1 publication Critical patent/CY1120670T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Παρέχονται απομονωμένα μονοκλωνικά αντισώματα που δεσμεύουν τον ανθρώπινο αναστολέα του μονοπατιού ιστικού παράγοντα (tissue factor pathway inhibitor, ΤFΡΙ) καθώς και τα απομονωμένα μόρια νουκλεϊνικού οξέος που κωδικοποιούν τα ως άνω αντισώματα. Παρέχονται επίσης φαρμακευτικές συνθέσεις που περιέχουν τα μονοκλωνικά αντισώματα αντι-ΤFΡΙ και μέθοδοι για τη θεραπευτική αντιμετώπιση ελλειμμάτων ή ελαττωμάτων στην πήξη με χορήγηση των αντισωμάτων. Παρέχονται επίσης και μέθοδοι για την παραγωγή των αντισωμάτων.
CY181100729T 2008-08-04 2018-07-11 Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) CY1120670T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8598008P 2008-08-04 2008-08-04
PCT/US2009/052702 WO2010017196A2 (en) 2008-08-04 2009-08-04 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
CY1120670T1 true CY1120670T1 (el) 2019-12-11

Family

ID=41664165

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100729T CY1120670T1 (el) 2008-08-04 2018-07-11 Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)

Country Status (35)

Country Link
US (3) US20120269817A1 (el)
EP (1) EP2321356B1 (el)
JP (1) JP5801194B2 (el)
KR (5) KR20180029106A (el)
CN (4) CN102143979B (el)
AU (3) AU2009279804C1 (el)
BR (2) BR122017025538A2 (el)
CA (4) CA3138035A1 (el)
CL (3) CL2011000230A1 (el)
CO (1) CO6351803A2 (el)
CR (1) CR20110066A (el)
CU (2) CU23880B1 (el)
CY (1) CY1120670T1 (el)
DK (1) DK2321356T3 (el)
DO (2) DOP2011000045A (el)
EC (1) ECSP11010810A (el)
ES (1) ES2677329T3 (el)
HR (1) HRP20181095T1 (el)
HU (1) HUE038648T2 (el)
IL (4) IL210987A (el)
LT (1) LT2321356T (el)
MX (1) MX2011001351A (el)
MY (1) MY161844A (el)
NZ (2) NZ731392A (el)
PE (2) PE20110771A1 (el)
PH (1) PH12017502286A1 (el)
PL (1) PL2321356T3 (el)
PT (1) PT2321356T (el)
SG (1) SG10201703066PA (el)
SI (1) SI2321356T1 (el)
SV (1) SV2011003828A (el)
TR (1) TR201807252T4 (el)
UA (2) UA112050C2 (el)
WO (1) WO2010017196A2 (el)
ZA (1) ZA201100888B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2379096T3 (da) 2008-12-19 2019-11-25 Baxalta GmbH TFPI-inhibitorer og fremgangsmåder til anvendelse
CA2745317C (en) † 2008-12-22 2019-03-05 Ida Hilden Antibodies against tissue factor pathway inhibitor
EP3216462A3 (en) * 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
AU2016269554B2 (en) * 2010-03-01 2018-12-20 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
DK3345615T3 (da) * 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
AU2013202745B2 (en) * 2010-03-01 2017-01-05 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
JP5730983B2 (ja) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
CA2800188A1 (en) * 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
EP2588499B1 (en) 2010-06-30 2020-04-08 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
DK2694544T3 (en) * 2011-04-01 2019-04-15 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAINST TIBI FACTOR ACTIVITY INHIBITOR (TFPI)
CN109111505A (zh) 2012-03-21 2019-01-01 百深有限责任公司 Tfpi抑制剂及其使用方法
KR20150030639A (ko) * 2012-03-30 2015-03-20 바이엘 헬스케어 엘엘씨 프로테아제로 조절된 항체
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9556280B2 (en) 2013-03-15 2017-01-31 Bayer Healthcare Llc Anti-TFPI antibody variants with differential binding across PH range for improved pharmacokinetics
EP3022228B1 (en) * 2013-07-19 2019-02-27 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
WO2016042093A1 (en) * 2014-09-17 2016-03-24 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
CN112225812B (zh) * 2015-02-25 2024-08-13 财团法人牧岩生命科学研究所 结合tfpi的新型抗体以及包含所述抗体的组合物
IL302353A (en) * 2015-08-19 2023-06-01 Pfizer TFPI inhibitory antibodies and their uses
JP6419664B2 (ja) * 2015-08-26 2018-11-07 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
MX2021004120A (es) 2018-10-11 2021-09-10 Pfizer Regimen de dosificacion para antagonistas de tfpi.
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN112552396B (zh) * 2020-12-30 2022-07-12 河南中泽生物工程有限公司 抗非洲猪瘟病毒p54蛋白单克隆抗体、制备方法及应用
JP2021091720A (ja) * 2021-03-03 2021-06-17 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6969586B1 (en) * 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JPH0875736A (ja) * 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
US20040052799A1 (en) * 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
AU3006799A (en) * 1998-03-12 1999-09-27 Human Genome Sciences, Inc. 31 human secreted proteins
JP2000128803A (ja) * 1998-10-19 2000-05-09 Shionogi & Co Ltd ティッシュ・ファクター・パスウェイ・インヒビター−２抗体
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
JP4623825B2 (ja) * 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) * 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) * 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CZ20023667A3 (cs) * 2000-05-10 2003-04-16 Novo Nordisk A/S Farmaceutický prostředek obsahující VIIA a XIII faktory
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US20020082206A1 (en) * 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
PT2275449T (pt) * 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) * 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
US20070020625A1 (en) * 2001-02-07 2007-01-25 Eric Duchaud Sequence of the photorhabdus luminescens strain tt01 genome and uses
US6891085B2 (en) * 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
AU2002302247A1 (en) * 2001-05-21 2002-12-03 Ecopia Biosciences Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
IL161408A0 (en) * 2001-10-15 2004-09-27 Chiron Corp Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20050108791A1 (en) * 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
WO2003065006A2 (en) * 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20060068386A1 (en) * 2002-03-04 2006-03-30 Alexei Slesarev Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
DK1549341T3 (da) * 2002-05-01 2009-07-06 Bayer Schering Pharma Ag Mod vævsfaktor rettede antistoffer som antikoagulanter
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP1539235A2 (en) * 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
DE10239073A1 (de) * 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
CA3007908A1 (en) * 2003-03-07 2005-04-14 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
BRPI0412885A (pt) * 2003-07-18 2006-10-03 Amgen Inc polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf)
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
EP2284184A3 (en) * 2004-01-09 2011-05-18 Novozymes, Inc. Bacillus YvmA inactivation
EP1838733B1 (en) * 2004-12-21 2011-08-24 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
WO2006081139A2 (en) * 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
SI1850873T1 (sl) * 2005-02-08 2019-05-31 Genzyme Corporation Protitelesa proti TGFBETA
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
EP1871883A1 (en) * 2005-03-02 2008-01-02 Metanomics GmbH Process for the production of fine chemicals
KR101434682B1 (ko) * 2005-12-02 2014-08-27 제넨테크, 인크. 결합 폴리펩티드 및 이들의 용도
EP2044118A2 (en) * 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
CA2745317C (en) * 2008-12-22 2019-03-05 Ida Hilden Antibodies against tissue factor pathway inhibitor
DK3345615T3 (da) * 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)

Also Published As

Publication number Publication date
DOP2019000287A (es) 2019-12-15
CL2011000230A1 (es) 2011-06-24
CA2733075C (en) 2018-10-23
JP2013500701A (ja) 2013-01-10
CR20110066A (es) 2011-05-25
IL250640A0 (en) 2017-04-30
CL2016003014A1 (es) 2017-06-30
MY161844A (en) 2017-05-15
CU23900B1 (es) 2013-03-28
CA3081514A1 (en) 2010-02-11
DK2321356T3 (en) 2018-07-23
CU20110031A7 (es) 2012-06-21
KR20160091439A (ko) 2016-08-02
AU2009279804B2 (en) 2016-03-24
CN102143979B (zh) 2016-08-03
PL2321356T3 (pl) 2018-10-31
CN110437335A (zh) 2019-11-12
CA2733075A1 (en) 2010-02-11
SV2011003828A (es) 2011-05-20
ECSP11010810A (es) 2011-03-31
PT2321356T (pt) 2018-07-17
CU20110236A7 (es) 2012-07-31
AU2009279804A1 (en) 2010-02-11
US20120269817A1 (en) 2012-10-25
EP2321356A4 (en) 2013-02-13
ZA201100888B (en) 2012-04-25
CN105944100A (zh) 2016-09-21
HUE038648T2 (hu) 2018-11-28
UA120596C2 (uk) 2020-01-10
ES2677329T3 (es) 2018-08-01
BR122017025538A2 (pt) 2021-01-19
CA3138035A1 (en) 2010-02-11
KR20180029106A (ko) 2018-03-19
CL2016003015A1 (es) 2017-06-30
KR20190099341A (ko) 2019-08-26
KR101769725B1 (ko) 2017-08-18
CA2933259A1 (en) 2010-02-11
PE20141563A1 (es) 2014-10-24
WO2010017196A3 (en) 2010-11-04
PE20110771A1 (es) 2011-10-14
CN110452299A (zh) 2019-11-15
CN102143979A (zh) 2011-08-03
IL210987A0 (en) 2011-04-28
CO6351803A2 (es) 2011-12-20
AU2016201230A1 (en) 2016-03-17
SG10201703066PA (en) 2017-05-30
IL277162B (en) 2021-05-31
AU2018203753A1 (en) 2018-06-21
EP2321356A2 (en) 2011-05-18
CU23880B1 (es) 2013-04-19
CN105944100B (zh) 2019-09-17
SI2321356T1 (sl) 2018-09-28
IL277162A (en) 2020-10-29
DOP2011000045A (es) 2011-10-31
EP2321356B1 (en) 2018-04-11
HRP20181095T1 (hr) 2018-09-21
PH12017502286A1 (en) 2019-11-11
IL282658A (en) 2021-06-30
LT2321356T (lt) 2018-09-10
AU2009279804C1 (en) 2017-01-19
KR101692085B1 (ko) 2017-01-03
IL210987A (en) 2017-03-30
CA2933259C (en) 2021-07-06
WO2010017196A2 (en) 2010-02-11
US20180334509A1 (en) 2018-11-22
MX2011001351A (es) 2011-10-12
JP5801194B2 (ja) 2015-10-28
BRPI0917418A2 (pt) 2021-01-05
UA112050C2 (uk) 2016-07-25
TR201807252T4 (tr) 2018-06-21
CA3081514C (en) 2021-12-14
IL250640B (en) 2020-10-29
NZ731392A (en) 2018-10-26
US20170342162A1 (en) 2017-11-30
NZ714313A (en) 2017-05-26
KR20110043736A (ko) 2011-04-27
KR20170005516A (ko) 2017-01-13

Similar Documents

Publication Publication Date Title
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1123739T1 (el) Αντισωματα anti-cd38
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1117986T1 (el) Ενωσεις αρυλ- ή ετεροαρυλ-υποκατεστημενου βενζολιου
EA201001639A1 (ru) Композиции и способы их получения и применения
CY1112813T1 (el) 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
UA107783C2 (en) Isoindoline compounds for use in treating cancer
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201100923A1 (ru) Антитела человека против тканевого фактора
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
CY1113551T1 (el) Υποκατεστημενες ενωσεις νικοτιναμιδιου και η χρησιμοποιηση τους σε φαρμακα
CY1120395T1 (el) Παραγωγα στερολης και χρηση αυτων για την αγωγη νοσηματων που περιλαμβανουν μετασχηματισμενα αστροκυτταρα ή για την αγωγη κακοηθων αιμοπαθειων
CY1115984T1 (el) Νεες amino αζαετεροκυκλικες καρβοξαμιδες